SatRx LLC Announces First Registration in Russia of SatRx® (gosogliptin), an Innovative Drug for Treatment of Type 2 Diabetes

SatRx LLC Announces First Registration in Russia of SatRx® (gosogliptin), an Innovative Drug for Treatment of Type 2 Diabetes

1 satrx3_200_main           chemdiv_logo1 chemrar_eng_logo_x200

SAN DIEGO, CA, June 9, 2016 – Today, at the largest global biotech forum, BIO International Convention, that took place in San Francisco, USA, SatRx LLC, a ChemRar / ChemDiv, Inc company, specializing in research and development in the fields of diabetes and cardiometabolic disorders, announced the first market registration of its innovative drug for the treatment of Type 2 diabetes, SatRx® (gosogliptin), in Russia.

According to the World Health Organization, diabetes is one of the four most socially significant diseases, responsible for 80% of deaths from non-communicable diseases worldwide. Diabetes affects one in ten people in the world, with Type 2 diabetes (or non-insulin-dependent diabetes) accounting for about 90% of all cases.

SatRx is a new drug for treatment of Type 2 diabetes that belongs to the class of inhibitors of dipeptidyl peptidase-4 (DPP-4, DPP-IV), the enzyme responsible for the fast inactivation of the incretin hormones that stimulate insulin secretion in response to food intake. By inhibiting the activity of DPP-4, SatRx prolongs the blood-life of incretin hormones, improving blood glucose control, enhancing the insulin secretory response, and increasing insulin sensitivity.

In 2012, SatRx LLC, a ChemRar / ChemDiv, Inc company, obtained an exclusive global (excluding China) license for the development, registration and commercialization of the Phase 2 drug candidate as well as its combinations from Pfizer Inc. SatRx secured an equity investment from ChemRar and a development contract with the Ministry of Industry and Trade of the Russian Federation under the framework of the “PharmaMed-2020” program, initiated by the Russian government to promote domestic drug development and modernization of the pharmaceutical industry. Under the “PharmaMed-2020” program, the Russian government plans for 90% of essential drugs to be produced locally by 2020.

“The first market registration of the SatRx drug is an important milestone for ChemRar in its commitment to developing breakthrough treatments, diagnostics, and mechanisms for monitoring and controlling diabetes,” stated Nikolay Savchuk, member of the Board of Directors of ChemRar High-Tech Center. “We are pleased to see that our cooperation with Pfizer will allow Russian patients with Type 2 diabetes to have access to new innovative medicines that have been developed internationally and will be manufactured domestically.”

About SatRx LLC

SatRx LLC, a pharmaceutical company established in 2010 as part of the ChemRar High-Tech Center, is focused on the development and registration of innovative drugs for the treatment of Type 2 diabetes and metabolic syndrome.


About ChemRar

ChemRar High-Tech Center (HTC) is a group of research, manufacturing, and investment companies engaged in the development, manufacturing and commercialization of innovative drugs for the treatment of patients with life threatening diseases in Russia and worldwide.


About ChemDiv and ChemDiv Research Institute
ChemDiv a global research organization based in San Diego, California. The ChemDiv Research Institute R&D facilities are located at Torrey Pines Center in San Diego, while the ChemRar High Tech Center and Skolkovo Life Science Cluster are located in Moscow. For 25 years ChemDiv accelerates and enables pharma and biotech R&D programs from research concepts to registered drugs, targeting broad spectrum of unmet medical needs.



Nikolay Savchuk
Managing Partner
Torrey Pines Investment
Member of the Board at ChemRar HTC

Share this:
June 14, 2016 / News